GH Research (NASDAQ:GHRS) Shares Down 3.1%

GH Research PLC (NASDAQ:GHRS - Get Free Report) fell 3.1% on Wednesday . The company traded as low as $10.54 and last traded at $10.65. 11,876 shares were traded during trading, a decline of 91% from the average session volume of 134,902 shares. The stock had previously closed at $10.99.

Analysts Set New Price Targets

Several research analysts recently issued reports on GHRS shares. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of GH Research in a research report on Monday, March 4th. JMP Securities reduced their target price on GH Research from $50.00 to $39.00 and set a "market outperform" rating on the stock in a research report on Friday, March 1st.

GH Research Price Performance

The business has a fifty day moving average price of $9.54 and a two-hundred day moving average price of $7.79. The firm has a market capitalization of $571.81 million, a price-to-earnings ratio of -16.12 and a beta of 0.84.

GH Research (NASDAQ:GHRS - Get Free Report) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). On average, research analysts predict that GH Research PLC will post -0.96 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of GHRS. Bank of America Corp DE grew its holdings in GH Research by 13,760.0% during the fourth quarter. Bank of America Corp DE now owns 2,772 shares of the company's stock worth $27,000 after acquiring an additional 2,752 shares during the period. Tower Research Capital LLC TRC grew its holdings in GH Research by 246.2% during the first quarter. Tower Research Capital LLC TRC now owns 4,075 shares of the company's stock worth $33,000 after acquiring an additional 2,898 shares during the period. Northern Trust Corp acquired a new stake in GH Research during the fourth quarter worth about $59,000. Renaissance Technologies LLC acquired a new stake in GH Research during the first quarter worth about $86,000. Finally, State Street Corp acquired a new stake in GH Research during the third quarter worth about $127,000. 56.90% of the stock is owned by institutional investors and hedge funds.

GH Research Company Profile

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD.